Gilead: Remdesivir Associated With Recovery, Reduction in Mortality Risk
July 10 2020 - 9:27AM
Dow Jones News
By Dave Sebastian
Gilead Sciences Inc. said a comparison of a late-stage
remdesivir trial with real-world treatment of patients with severe
Covid-19 found that the drug suggests clinical recovery and a 62%
reduction in mortality risk.
The Food and Drug Administration has authorized remdesivir for
emergency use for the treatment of severe Covid-19, though it
hasn't established the drug's safety and efficacy. Several U.S.
states are seeing a resurgence in the disease caused by the new
coronavirus as the race to develop Covid-19 vaccines and treatments
continues.
About three-quarters of patients treated with remdesivir
recovered by the second week, compared with 59% of patients who
received standard care, Gilead said. The death rate of
remdesivir-treated patients was 7.6% on Day 14, while the rate
among patients who didn't take remdesivir was 12.5%, the company
said.
The company said patients of traditionally marginalized racial
and ethnic subgroups treated with remdesivir had similar outcomes
as the overall patient population.
Gilead said 83% of pediatric patients and 92% of pregnant and
postpartum women in the study recovered by the 28th day of
treatment.
The Phase 3 study involved 312 patients and a separate cohort of
818 patients who received standard care in the same time period,
Gilead said. Those patients were mostly located in North America,
with others in Europe and Asia.
The comparative study adds to the previous National Institute
Allergy and Infectious Disease study, which found that
remdesivir-taking patients had a lower death rate compared with
those who didn't take the drug. The NIAID study didn't reach
statistical significance.
Gilead late last month said it will charge U.S. hospitals $3,120
for a typical patient using remdesivir. The U.S. has been
distributing remdesivir donated by Gilead since the drug was
authorized for emergency use in May.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
July 10, 2020 09:12 ET (13:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024
